- clinical-studies-(clinical-trial) (6)
- fundamental (3)
- acute-phase-protein (1)
- biomarker (1)
- clinical-studies-(observational) (1)
- controlled (1)
- convalescent-plasma (1)
- covid-19 (1)
- covid-19-chloroquine-caregivers-in-luxembourg-clinical-trial (1)
- covid19-hydroxychloroquine-favipiravirlopinavir/ritonavir-non-hospitalized-gp-clinical-trial (1)
Cytokines as biomarkers and therapeutic targets in COVID-19 infection
Cytokines play an important role in the pathogenesis of COVID-19 infection. A subgroup of patients develops a cytokine storm syndrome, correlating with a bad clinical outcome. For example, the concentration of the inflammatory cytokine Interleukin-6 (IL-6) has been recognized as a risk factor for mortality and for respiratory failure in Chinese and German patient cohorts, respectively. Tocilizumab, an antibody directed against the IL-6 receptor alpha chain, is used in clinical trials as well as an FDA-approved inhibitor of Jaks, tyrosine kinases which mediate the signal transduction of mult...
OPEN LABEL RANDOMIZED CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF PLASMA THERAPY FROM RECOVERE...
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19. Currently there are no approved therapeutic agents available for coronaviruses. The purpose of this trial is to provide substantial evidence on the efficacy and safety of the treatment of selected COVID-19 patients with plasma obtained from convalescent COVID-19 patients ('PLASMA').
COVAMBU: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COV...
The purpose of this Multi-centre, adaptive, randomized trial is to provide substantial evidence on the efficacy, or lack of efficacy and safety of treatments available in Luxembourg, given to COVID-19 positive-testing-patients who do not yet require hospitalization. Efficacy will be assessed through virological response and clinical outcomes.
Prophylaxis: Chloroquine or hydroxychloroquine prevention of COVID-19 disease for caregivers in L...
The aim of this clinical trial is to determine if prophylactic chloroquine or hydroxychloroquine prevents symptomatic COVID-19 illness health care workers in Luxembourg. The secondary objectives include: • Attenuation of the clinical severity of COVID-19 infections. • The prevention of asymptomatic COVID-19. • The prevention of symptomatic all-cause acute respiratory illnesses (ARI).
COVID19-induced changes to the plasma proteome
Studies focussing on human coronavirus found so far seven different viruses including SARS, MERS and COVID19. SARS, MERS and COVID19 present with various flu-like symptoms up to respiratory distress. Secondary symptoms include kidney problems, cardiovascular problems and neurological signs, like headache and nausea. In the case of the SARS infection, it has been shown that the virus can invade the central nervous system in patients and laboratory animals. The infection of epithelial cells by a coronavirus will lead to a change of the cellular protein composition in response to the virus' ...
Development of a MS-based COVID19 test
The project aims on developing an alternative test for the detection of corona virae based on proteomic methods. The advatage of the use of proteins is that the samples do not have to be cooled and can be transported at room temperature to the analytical lab.